September 1, 2000Transplantation
INTRAGRAFT INTERLEUKIN-4 mRNA EXPRESSION AFTER SHORT-TERM CD154 BLOCKADE MAY TRIGGER DELAYED DEVELOPMENT OF TRANSPLANT ARTERIOSCLEROSIS IN THE ABSENCE OF CD8+ T CELLS1
Key result
Combined treatment with anti-CD154 and a depleting CD8 mAb delayed transplant arteriosclerosis at day 30 (33% vs 67%) but did not prevent its progression by day 50 (55% vs 78%).
Why the study?
Does combined treatment with anti-CD154 and anti-CD8 mAbs prevent transplant arteriosclerosis in a murine aortic allograft model?
Population
C57BL/6 (H2b) mice receiving a fully MHC-mismatched BALB/c donor aorta (H2d)
Comparison
Anti-CD154 monoclonal antibody combined with a… vs Untreated control
Design
Preclinical
Follow-up
50 days
Authors
Discussion
Loading...
Member takes
Implication
Short-term anti-CD154 plus CD8 depletion fails to prevent arteriosclerosis progression in this model; leaves open sustained immunomodulation strategies for chronic allograft vasculopathy.
Structured PICO
Does combined treatment with anti-CD154 and anti-CD8 mAbs prevent transplant arteriosclerosis in a murine aortic allograft model?
P
Population
C57BL/6 mice receiving a fully MHC-mismatched BALB/c donor aorta, treated with anti-CD154 mAb with or without CD8 T cell depletion, followed for up to 50 days.
I
Intervention
Anti-CD154 monoclonal antibody (mAb) combined with a depleting CD8 mAb
C
Comparator
Untreated control
O
Outcome
Development of transplant arteriosclerosis (intimal proliferation) at days 14, 30, and 50surrogate
Main Result
Absolute Event Rate: 55% vs 78%
Short-term CD154 blockade combined with CD8+ T-cell depletion delays but does not prevent transplant arteriosclerosis, potentially due to increased intragraft IL-4 expression.
Cite This Study
Ensminger et al. (2000) studied Transplant arteriosclerosis. Combined treatment with anti-CD154 and a depleting CD8 mAb vs. Untreated control was evaluated on Intimal proliferation at day 50. Combined treatment with anti-CD154 and a depleting CD8 mAb delayed transplant arteriosclerosis at day 30 (33% vs 67%) but did not prevent its progression by day 50 (55% vs 78%).